[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2019

October 2019 | 60 pages | ID: IECE1AE92F25EN
DelveInsight

US$ 1,000.00 US$ 1,250.00 -20 %
Offer valid until December 31, 2019!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 48 Hours

'Intrahepatic Cholangiocarcinoma (ICC) - Pipeline Insight, 2019' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Intrahepatic Cholangiocarcinoma pipeline landscape is provided which includes the disease overview and Intrahepatic Cholangiocarcinoma treatment guidelines. The assessment part of the report embraces, in depth Intrahepatic Cholangiocarcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Intrahepatic Cholangiocarcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Intrahepatic Cholangiocarcinoma Understanding

Intrahepatic Cholangiocarcinoma (ICC) originated from the liver parenchyma beyond the second order bile ducts and belongs to a family of aggressive Cholangiocarcinomas, a rare and heterogeneous malignant neoplasm with epithelial cell of biliary duct and has the histologic and biochemical features of cholangiocyte differentiation. Receptor tyrosine kinases such as IL-6 receptor, c-MET, and the EGFR family members ERBB2 and ERBB1 are key signaling pathways in ICC. Aberrant activation of these receptor tyrosine kinases causes constitutive activation of downstream signaling cascades (i.e., JAK/ STAT3, PI3K/Akt, ERK1/2, and p38MAPK) resulting in dysregulation of cell senescence, cell cycle regulation and proliferation, and apoptosis. Common symptoms of ICC include malaise, cachexia, abdominal pain, night sweats, fatigue and/or jaundice, associated or not with systemic manifestations, etc. The risk factors for developing ICC includes Primary sclerosing cholangitis, parasitic infections, intrahepatic biliary stones (hepatolithiasis), liver cirrhosis, viral infection, and others. The recently proposed classification of ICCs subdivided the tumors into conventional, bile ductular, or intraductal neoplasm type, or rare variants (combined hepatocellular ICC, undifferentiated ICC, squamous/adenosquamous type). The conventional type include a small duct or peripheral type and large duct or perihilar type. The bile ductular and combined hepatocellular-ICC might have originated from hepatic progenitor cells (HPCs) (as a neural cell adhesion molecule, a marker of HPC has been detected).

Intrahepatic Cholangiocarcinoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Intrahepatic Cholangiocarcinoma targeted therapeutics development with respective active and dormant or discontinued projects. Intrahepatic Cholangiocarcinoma pipeline report covers 17+ companies. Some of the key players include Delcath Systems (Melphalan/HDS), Sirnaomics (STP705), RedHill Biopharma (Opaganib), etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Intrahepatic Cholangiocarcinoma Analytical Perspective by DelveInsight
  • In-depth Intrahepatic Cholangiocarcinoma Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Intrahepatic Cholangiocarcinoma Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

SCOPE OF THE REPORT
  • The Intrahepatic Cholangiocarcinoma report provides an overview of therapeutic pipeline activity for Intrahepatic Cholangiocarcinoma across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Intrahepatic Cholangiocarcinoma therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Intrahepatic Cholangiocarcinoma Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Intrahepatic Cholangiocarcinoma
REASONS TO BUY
  • Establish a comprehensive understanding of the current pipeline scenario across Intrahepatic Cholangiocarcinoma to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Intrahepatic Cholangiocarcinoma R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Intrahepatic Cholangiocarcinoma in licensing and out licensing strategies by identifying prospective partners with progressing projects for Intrahepatic Cholangiocarcinoma to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. INTRAHEPATIC CHOLANGIOCARCINOMA

2.1. Intrahepatic Cholangiocarcinoma Disease Overview
2.2. Intrahepatic Cholangiocarcinoma History
2.3. Intrahepatic Cholangiocarcinoma Symptoms
2.4. Intrahepatic Cholangiocarcinoma Causes
2.5. Intrahepatic Cholangiocarcinoma Pathophysiology
2.6. Intrahepatic Cholangiocarcinoma Diagnosis
  2.6.1. Diagnostic Guidelines

3. INTRAHEPATIC CHOLANGIOCARCINOMA CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. INTRAHEPATIC CHOLANGIOCARCINOMA - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Intrahepatic Cholangiocarcinoma companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Intrahepatic Cholangiocarcinoma Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Intrahepatic Cholangiocarcinoma Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. INTRAHEPATIC CHOLANGIOCARCINOMA PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. INTRAHEPATIC CHOLANGIOCARCINOMA - PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Melphalan: Delcath Systems
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
  6.1.2. STP705: Sirnaomics
    6.1.2.1. Product Description
      6.1.2.1.1. Product Overview
      6.1.2.1.2. Mechanism of Action
    6.1.2.2. Research and Development
      6.1.2.2.1. Clinical Studies
        6.1.2.2.1.1. Detailed Study Description
        6.1.2.2.1.2. Study Results
        6.1.2.2.1.3. Clinical Trials: Tabular View
    6.1.2.3. Product Development Activities
      6.1.2.3.1. Tabulated Product Summary
        6.1.2.3.1.1. General Description Table
  6.1.3. Opaganib: RedHill Biopharma
    6.1.3.1. Product Description
      6.1.3.1.1. Product Overview
      6.1.3.1.2. Mechanism of Action
    6.1.3.2. Research and Development
      6.1.3.2.1. Clinical Studies
        6.1.3.2.1.1. Detailed Study Description
        6.1.3.2.1.2. Study Results
        6.1.3.2.1.3. Clinical Trials: Tabular View
    6.1.3.3. Product Development Activities
      6.1.3.3.1. Tabulated Product Summary
        6.1.3.3.1.1. General Description Table

7. RECENT TECHNOLOGIES

8. INTRAHEPATIC CHOLANGIOCARCINOMA KEY COMPANIES

8.1. ArQule
8.2. H3 Biomedicine
8.3. Delcath System
8.4. Sirnaomics
8.5. RedHill Biopharma
8.6. Roche
8.7. Forma Therapeutics
8.8. Jiangsu Hengrui Medicine
8.9. Biocompatibles International
8.10. LSK BioPartners
8.11. Eisai Co Ltd
8.12. Array BioPharma
8.13. Bayer Healthcare
8.14. Taiho Oncology
8.15. Sirtex Medical
8.16. MedImmune
8.17. Rafael Pharmaceuticals

9. INTRAHEPATIC CHOLANGIOCARCINOMA KEY PRODUCTS

9.1. Derazantinib
9.2. H3B 6527
9.3. Melphalan (Primary)
9.4. STP
9.5. Opaganib
9.6. Capecitabine (Primary) ; Yttrium-90 (Primary)
9.7. FT 2102
9.8. Camrelizumab
9.9. Irinotecan-eluting beads
9.10. Rivoceranib
9.11. Lenvatinib
9.12. Varlitinib
9.13. Regorafenib
9.14. Futibatinib
9.15. Cisplatin-gemcitabine
9.16. Durvalumab
9.17. CPI

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. INTRAHEPATIC CHOLANGIOCARCINOMA - UNMET NEEDS

12. INTRAHEPATIC CHOLANGIOCARCINOMA - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Intrahepatic Cholangiocarcinoma Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Intrahepatic Cholangiocarcinoma companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Intrahepatic Cholangiocarcinoma Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

ArQule
H3 Biomedicine
Delcath System
Sirnaomics
Millennium Pharmaceuticals
RedHill Biopharma
Roche
Forma Therapeutics
Jiangsu Hengrui Medicine
Biocompatibles International
LSK BioPartners
Pfizer
Eisai Co Ltd
Array BioPharma
Bayer Healthcare
Taiho Oncology
MedImmune
Genentech
Rafael Pharmaceuticals
Sirtex Medical



More Publications